What is Evommune 's issuance of warrants?

Evommune (EVMN) reported issuance of warrants of $150 in Q4 2025.

What does issuance of warrants mean?

Reflects the accounting adjustments made to additional paid-in capital specifically related to the issuance of stock warrants. This captures the non-cash equity impact of granting rights to purchase shares at a future date. Investors use this to assess the potential future dilution and the cost of equity-linked financing instruments.

Evommune EVMN Issuance of warrants

Issuance of warrants at other companies

Oruka Therapeutics, Inc.ORKA

$2.52M-75.7%

Evommune EVMN

$150—

ADMA BiologicsADMA

$1.4M—

Taysha Gene Therapies, Inc.TSHA

$409.25K—

Applied DigitalAPLD

$121.2M+232%

KEE

Keel Infrastructure Corp. Common StockKEEL

$11.48M—

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's issuance of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's issuance of warrants?: Evommune (EVMN) reported issuance of warrants of $150 in Q4 2025.
What does issuance of warrants mean?: Reflects the accounting adjustments made to additional paid-in capital specifically related to the issuance of stock warrants. This captures the non-cash equity impact of granting rights to purchase shares at a future date. Investors use this to assess the potential future dilution and the cost of equity-linked financing instruments.